ZNF462

Across TCGA pan-cancer cohorts, ZNF462 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF462 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ZNF462 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZNF462 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where ZNF462 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.945	0.567	.009	13	view →
PDAC	OS	Median	II,III,IV	0.405	0.725	.020	12	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.905	.032	5	view →
GBM	OS	Median	All	0.922	0.791	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF462–LSCC (OS)

Open the LSCC breakdown →